Data / Form D filings / Hemostemix Inc.
Hemostemix Inc.: Form D filing
Hemostemix Inc., a biotechnology company in Blackfalds, Alberta, Canada, filed a Form D with the SEC in 2017. The latest, on September 14, 2017, reports an offering of $132,071 with nothing sold yet to 2 investors.
Find out what Hemostemix Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- BAY 1, 5220 DUNCAN AVENUE, PO BOX 10, Blackfalds, Alberta, Canada, T0M 0
- Phone
- (403) 340-9207
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Alberta, Canada
- Year incorporated
- 2014
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(c)
- SEC identifier (CIK)
- 1716567
The full lists. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Form D filings: 44,302 rows, $523.02, or the new rows each week for $92.05 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Sep 14, 2017 | New notice | $132,071 | $0 | $132,071 | 2 | Aug 25, 2017 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Angus Jenkins | Director | |
| Don L. Friesen | Director | |
| Ina L. Sarel | Executive Officer | |
| Kyle L. Makofka | Executive Officer | |
| David L. Berman | Executive Officer | |
| David L. Wood | Director |
Every Form D from the week of Sep 11, 2017 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Hemostemix Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.